TP53 and non-small cell lung carcinoma: This study demonstrated the efficacy of co-delivering an adenoviral vector encoding an ABE and guide RNAs targeting EGFR T790M and TP53 R273H in gefitinib-resistant H1975 non-small cell lung cancer (NSCLC) harboring these mutations.